uppsala biotech master case overview

The Uppsala Biotech Master CaseOverview

Dr. Robin Teigland, Master Case FacilitatorMaster of Business Administration Program (MBA)

Stockholm School of Economics (SSE)April to June 2005

www.sse.edu/ssemba

Purpose

• The purpose of this document is to provide potential MBA students with a flavor of MBA Live by presenting an overview of the Uppsala Biotech Master Case that took place April to June 2005.

• This document describes some of the activities and events during this Master Case and is based on actual materials used.

• If there are any questions about this Master Case or about MBALive in general, please do not hesitate to contact Master Case Coach Robin Teigland at [email protected]. More information on Robin Teigland can also be found at www.knowledgenetworking.org.

Overview of Uppsala Biotech Master Case

• Introduction to SSE MBA Students

• Introduction to Uppsala Biotech Master Case

• Overview of Uppsala Biotech MC Phase I Dynamics of Regional Innovation Systems with Prof. Walshok

Uppsala Biotech Master Case Kick-off in Uppsala

Phase I Deliverables

Biotech Day I

• Overview of Uppsala Biotech MC Phase II Dynamics of Regional Innovation Systems with Prof. Walshok, trip to San

Diego

Phase II Deliverables

Biotech Symposium

Countries representedSweden (25%) United States Latvia GermanyEstonia FranceJapan IcelandVenezuela/Spain NetherlandsDenmark IndiaArgentina TurkeySwitzerland United KingdomGreece

Total of 36 studentsAverage age: 31Average no. working years: 6.5

20%

80%

Female

Male

10%

19%

32%

39%

Law Other

Engineering BusAdm/ Econ

SSE MBA Students – Class of 2005

Educational background

Björn Svensson43, Sweden

Management ConsultantCap Gemini

Peter Vriesman32, Holland

Engineer, Electrolux

Santosh Nair, India28, BSc BusinessProject Manager Patrik Bosander

32, London, MSc KTHManaging Director

UK software provider

Arwen Schreiber, USA28, BA, Operations

Silicon Valley startups

Karin Fisher, 30Hong Kong, BA, Founder

Asian media startup

Jeanette Del Valle, 36Venezuela, BA

General Manager Entertainment firm

Taavi Lepmets30, Latvia, Founder

LHV, largest investment bank in Baltics

Roger Jacobsson, 37Sweden, EricssonBusiness Manager

Some SSE MBA Students

Richard Brorsson, SE34, MSc Business,

Business Development ManagerEuropean Commission







Biotech Day I


Diego


Biotech Symposium

The Three SSE MBA Master Cases in 2004-2005

• Pulp and paper products• Capital-intensive• Seven centuries old• Large multinational• Publicly listed• B2B

• Financial services• Information-intensive• Mid-sized national company• Strong local roots• Customer-owned (federation)• B2C

• Biotech• Knowledge-intensive• Networked organizations• From start-ups to large firms• Ethically complex• B2B, B2C, “Research 2 Business”

MC1 (Fall): StoraEnso

MC2 (Winter): LF (Länsförsäkringar)

MC3 (Spring): The Uppsala Biotech Cluster

The Uppsala Biotech Master Case• A collaborative effort that runs April to June 2005 between Uppsala BIO and SSE in which

students put their MBA skills into action• An opportunity for a number of Uppsala biotech organizations to get qualified external

insights on a current Key Issue in their organization Six Uppsala Biotech Sponsor Organizations each appointed a dedicated MBA Team of students

(6 students per MBA Team) to work on a Key Issue • Students conduct independent, theory-informed analyses of the Key Issue and…• ….produce and present a report with recommendations on the Key Issue for their UB

Sponsor Organization Opportunity to interact and learn together with an international, experienced group of

MBA students• Each student spends approximately 100 working hours on the UB Master Case, totaling

around 600 person-hours to work with each UB Sponsor Organization and analyze its Key Issue!

• An opportunity for Uppsala BIO and its firms to gain informed insights into innovation and entrepreneurial processes and cluster dynamics from across the globe

The Uppsala Biotech Master Case: Integrating the Micro and Macro Levels

Issues Shaping Nordic Competitiveness in Bioscience: The Uppsala CaseEach MBA Team investigates the issues shaping the competitiveness of the Uppsala Biotech Cluster and forms an opinion on how competitiveness could be improved

MC Sponsor Organization Key Issue

Each MBA Team investigates and develops recommendations for a Key Issue for one Uppsala Biotech Sponsor Organization

What is Biotechnology?

A group of techniques and technologies that apply the principles of genetics, immunology, and molecular, cellular and structural biology to the discovery and development of novel products

– Audretsch 2001

What is a Biotechnology Cluster?

Biotec

h firm

s

Other firms, e.g.,

suppliers,

customers

Academ

ic and priv

ate

rese

arch org

anizatio

ns

InteractionInteraction

Financing and

venture capital firms

Government, e.g., policy makers, funding agencies,

etc.

Support organizations, e.g., patent, consulting &

law firms, etc.

Enhanced innovation through

local interaction

Uppsala – A Biotech Hotbed

One of the world’s most biotech-concentrated cities?

1) Tools for life science2) Pharmaceuticals and biomedical devices3) Diagnostics

ExpertiseAreas

More information at www.uppsalabio.com

Century Scientist Achievement Nobel prize

18th O. Rudbeck The lymphatic system

18th C. Linnæus Systema Naturæ classification

18th A. Celcius Thermometric scale (°C)

18th J.J. Berzelius Chemical elements (Se, Th, Si, Ti, Z)

19th A. J. Ångström Modern spectroscopy (Å unit)

19-20th M. Siegbahn X-ray spectroscopy

19-20th T. Svedberg Ultracentrifuge

20th A. Tiselius Electrophoresis

20th K. Siegbahn Electron spectroscopy

20th J.Porath, P. Flodin Gel filtration

20th G. Johansson, Immunoglobulin E

H. Bennich, L. Wide

C. Linnæus

T. Svedberg

A. Tiselius

Unbroken Tradition of Scientific Achievement in Uppsala

Uppsala Biotech Master Case: Focused yet Combined with Seeing the Big Picture

Phase I. Sponsor Organization Key Issue Each MBA Team works with one Uppsala Biotech Sponsor

Organization to investigate and develop recommendations for a Key Issue for that organization

Key Issues may be related to financing, strategy, marketing, organization, operations, etc. (See appendix for suggestions.)

Phase II. Cluster Dynamics and Nordic Competitiveness in Biotechnology Each MBA Team works on developing an understanding of the

competitiveness of the Uppsala Biotech Cluster as well as participates in the SSE MBA Symposium on Issues Shaping Nordic Competitiveness in Biotechnology

Sponsor Organizations in the Uppsala Biotech Master Case

Larg

er fi

rms:

Phar

mac

ia

Diagnos

tics,

GE

Health

care

Funding agencies, e.g.,

Vinnova

Researc

h organiza

tions,

e.g.,

BMC, Rudbeck

, Ångstr

öm

InteractionInteraction

Venture capital:

HealthCap

Smaller organizations: BIO-X,QUIAtech, Resistentia,

Svanova

Support organizations, e.g.,

Uppsala Innovation Center, Uppsala BIO,

Intersecta

Cluster dynamics

Sponsor organizations in red

Cooperation with the Uppsala Bio Cluster Initiative

Madeleine Neil Uppsala BIO Communications018-57 23 53 0768-29 77 [email protected]

•An initiative between the local biotech industry, two Uppsala universities, and regional development bodies

•Goal: To establish the Uppsala – Stockholm region as one of the world’s five leading biotech regions within five years

Uppsala Biotech MC Sponsor Organizations

2004 0 Cross-disciplinary research project with researchers from academia and industry to develop tools for analysis of biomolecules

2000 ~15 Developing tools for genetic analysis, molecular diagnostics, and gene-based therapeutics

1998 ~20 Developing vaccines for treatment of allergies and asthma

2001 ~25 Offering products for diagnosing infectious diseases in livestock

1950s ~600 World leader in blood allergy testing

1940s ~1500 Developing systems & tools for discovery and development of drugs and for manufacture of biopharmaceuticals

Yearfounded

in Uppsala

No.empl. Company description

BIO-X

Uppsala Biotech MC - SchedulePhase I Sponsor Organization Key Issue

April 12-15 •Dynamics of Regional Innovation Systems I (With Prof. Walshok)

Tools for mapping the Uppsala Biotech Cluster

April 22 •Kick-off Day in UppsalaMeet Uppsala BIO, researchers, Sponsor Organizations, and CEF participants

April 25 – June 3 •Sponsor Organization Key Issue Key Issue developmentKey Issue analysis and recommendations preparation

June 3 •Uppsala Bio Day I at SSE Key Issue Report Presentation to Sponsor Organizations

Phase II Nordic Competitiveness in Biotechnology

June 6 - 30 •Dynamics of Regional Innovations Systems II (With Prof. Walshok)

Comparing cluster dynamics – Uppsala and San DiegoTrip to San Diego

•Nordic Competitiveness in BiotechnologyInvestigation and assignment preparation

June 30 •SSE MBA SymposiumSymposium on Issues Shaping Nordic Competitiveness in Biotechnology

Uppsala Biotech MC Activities and Supporting Deliverables

Phase I Activity:Sponsor Organization Key Issue Deliverable

Kick-off Regional Innovation System Presentation

Team field visit Field Visit Poster

Developing the key issue Key Issue Description

Developing key issue recommendations

Group Presentation: Key Issue Description & Solution Sketch

Uppsala Biotech Day I Presentation of Key Issue Recommendations

Delivering value Key Issue Recommendations Final Report

Phase II Activity:Nordic Competitiveness in Biotechnology

Deliverable

Forming an opinion Poster Presentation & Hand-out

Presenting an opinion Participation in SSE MBA Symposium

Uppsala Biotech MC Deliverables at a Glance

Phase I Deliverable:Sponsor Organization Key Issue

Due Presented

%grade

Regional Innovation System Presentation

April 20 April 22 --

Field Visit Poster April 25, 13:15 April 25 --

Key Issue Description May 4, 23:59 May 6 10

Group Presentation: Key Issue Description & Solution Sketch

May 11, 23:59 May 13 10

Presentation of Recommendation to Sponsor Organization

May 27, 23:59 June 350

Key Issue Recommendation Final Report

June 12, 13:00 N/A

Phase II Deliverable: Nordic Competitiveness in Biotechnology

Poster Presentation & Hand-out June 28, midnight

June 30 30

Participation in Symposium June 30 --







Biotech Day I


Diego


Biotech Symposium

The Dynamics of Regional Innovation Systems I Course

Visiting Professor Mary Walshok, Univ. Of California, San Diego

April 12-15Objectives I• To differentiate between the dynamics of innovation in corporate

environments and regional clusters

• To understand the critical components of entrepreneurial regional innovation systems

Objectives II• To map the capabilities and shortcomings of the Uppsala Biotech

Cluster

• To have an understanding of the complementarities of the business and financial services clusters in the Stockholm region for Uppsala’s R&D capabilities

Results to be presented by students at the Uppsala Biotech Kick-off in Uppsala for the Uppsala Bio Cluster Initiative

The Uppsala Biotech Master CaseKick-off

Master of Business Administration Program (MBA)Stockholm School of Economics (SSE)

April 22, 2005

Robin Teigland, 070 781 4422Martin Vidaeus, 070 232 2929

Master Case Kick-off Day in Uppsala Friday, April 22

• Bus leaves Sveavägen 65 (Leaves at 8:30 sharp)• MBA Teams visit Uppsala BIO (1)

Presentation by MBA Teams to Uppsala BIO based on the Dynamics of Regional Innovation Systems course

• MBA Teams visit Ångström, BMC, and Rudbeck Research Labs (2) Lunch Presentation of research projects and labs

• MBA Teams visit their Sponsor Organization (3) Introduction and discussion of practicalities

• Mingle Dinner with Sponsor Organizations (4) At Värmlands Nation with Sponsor Organization

Representatives Bus leaves from Domkyrkan, 8:45 pm

12:30-15:00

15:30-17:30

18:00-20:30

9:30-12:00

8:15

(1) Uppsala BIO – Science Park (9:30 -12:00)Dag Hammarskjölds väg 60, Uppsala

(The bus will leave Sveavägen 65 at 8:30 sharp!)

Madeleine Neil Uppsala BIO 018-57 23 53 0768-29 77 [email protected]

By train:www.sj.seDeparts ArrivesStockholm C Uppsala 7:40 -> 8:20 8:10 -> 8:50 8:40 -> 9:20

Map of Uppsala Bio and Research Labs

UppsalaBIO

(2) Visit to Research Labs (12:30 – 15:00)• BMC Lab, www.bmc.uu.se

Resistentia and Svanova teams Lab contact: Catharina Svensson, [email protected], tel:

018-471 4531 or 070-425 0385 MBA contact: Barbara Kraus, [email protected]

• Rudbeck Lab, www.rudbeck.uu.se BIO-X and Pharmacia teams Lab contact: Mats Nilsson, [email protected], tel: 018-4714816 or 073-

0537876 MBA contact: Rickard Brorsson, [email protected]

• Ångström Lab, www.angstrom.uu.se QUIAtech and GE teams Lab contact: Jan-Åke Schweitz, [email protected], tel: 018-

471 30 89 MBA contact: Gabriel Catrina, [email protected]

(2) Uppsala Biotech MC Teams

BIO-X QUIAtech Resistentia

Rickard Brorsson Gabriel Catrina Barbara Kraus

Jeanette Del Valle Tony Friede Stephan Kuratli

Einar Gudmundsson Christine Edman Sebastian Lang

Hans Johanssson Sören Holmblad Santosh Nair

Alexandrs Pjatibratovs Emil Sunvisson Pontus Nylander

Björn Svensson Dheva Raja Evaggelos Sempoglou

Pharmacia GE Svanova

Håkan Bengtsson Dogan Gegeoglu Erin Donaldson

Eriks Ciguzis Patrik Bosander Magnus Fernström

Jason Francis Karin Fisher Jerome Panoff

Hester Fenwick Peter Vriesman Moritz Wendt

Kristine Zelmene Krish Sailam Jun Okamoto

Arwen Schreiber Roger Jacobsson Taavi Lepmets

Rudbeck Lab

Student names in red are team contacts

Ångström Lab BMC Lab

(3a) Visit to Sponsor Organizations (15:30 – 17:30)

• BIO-X Company contact: Rhiannon Sanders, [email protected] www.uppsalabio.com, Tel: 070 601 93 20 Located in Uppsala BIO’s offices MBA contact: Rickard Brorsson, [email protected]

• GE Healthcare Company contact: Sven Henrichwark, [email protected] www.amershambiosciences.com, Tel: 018 612 0000 Located at Björkgatan 30, Uppsala MBA contact Dogan Gegeoglu, [email protected]

• Pharmacia Company contact: Håkan Englund, [email protected] www.diagnostics.com, Tel: 018 16 50 60 Located at Rapsgatan 7, Uppsala MBA contact: Håkan Bengtsson, [email protected]

(3b) Visit to Sponsor Organizations (15:30 – 17:30)

• QUIAtech Company contact: Karen Frost, [email protected] www.quiatech.com, Tel: 018 57 23 80 Located in Uppsala Science Park MBA contact: Gabriel Catrina, [email protected]

• Resistentia Company contact: Bingze Xu, [email protected] www.resistentia.se, Tel: 018 65 39 00 Located at Kungsängsvägen 25 (near E4 entrance to Uppsala) MBA contact: Barbara Kraus, [email protected]

• Svanova Company contact: Christina Frimodig, [email protected] www.svanova.com, Tel: 018 65 49 00 Located in Uppsala Science Park MBA contact: Erin Donaldson, [email protected]

(3c) Sponsor Organization Kick-off Visit:Suggested Activities

• Presentations MBA Team presents itself Key individuals from Sponsor Organization present themselves, e.g., CEO, Business

Development, Marketing, R&D, Finance, etc. Presentation of Sponsor Organization and brief overview of Key Issue

• Provide MBA Team with potential resources, e.g., documents, information, etc.

• Discussion of practicalities Scheduling of subsequent meeting times for Key Issue analysis and recommendations Confidentiality, i.e., protection of intellectual property and sensitive company

documents Rules of engagement, i.e., Sponsor Organizations may want to clearly define whom

MBA Team may contact and how they shall represent the Sponsor Organization in order to protect relationships with potential or active investors, customers, collaboration partners, etc.

Use of internal resources, e.g., internal marketing or business strategy documents, top-level R&D reports, and their return to the Sponsor Organization

Acquisition of external resources, e.g., basic cell biology primer references, third party market research studies, company reports, etc.

(4) Mingle Dinner at Värmlands Nation, (18-20:30, Bus leaves at 20:45)

• Värmlands nation Contact: Erik Holmquist,[email protected] www.varmlandsnation.se, Tel: 018 13 44 45 Located at Nedre Slottsgatan 2

• Departure for Stockholm By bus

• 8:45 pm • At Domkyrkan

By trainwww.sj.se

Departs Arrives

Uppsala Stockholm

20:10 -> 20:50

21:10 -> 21:50

21:27 -> 22:05

(4) Mingle with CEF Students

• We will be joined at the dinner by students from the Masters program at the Centre for Entrepreneurship and Enterprise Development at Uppsala University. Small program with 25 students per year

Students have a background in science and engineering and are interested in business development and entrepreneurship

The one-year program combines courses (business development, marketing, IPR and contract law, negotiation, organization theory and management, leadership, teambuilding, and emotional competence) with a live innovation project with an Uppsala firm

For more information, see http://www.cef.uu.se/ (in Swedish)

The Uppsala Biotech Master CasePhase I Deliverables


June 2, 2005

How to ensure research project success?

How to commercialize a technology?

How to develop a technology more efficiently?

How to increase market share in existing products in existing geographical markets?

How to enter an existing geographical market with a new product?

How to increase profits on existing products in existing markets?

Uppsala Biotech MC Sponsor Organizations & Key Issues*

BIO-X

*Projects have been generalized due to confidentiality aspects.

The Next Few Weeks in Phase I

• Friday, June 3rd Biotech Day I 5 minute Presentation of project for all students and company

reps Final Presentation of Key Issue for Sponsor Organization

• Sunday, June 12th Final Report due 13:00

• Monday, June 13th Assignment of groups for Phase II of Uppsala Biotech Master

Case More information on June 13th

Uppsala Biotech MC Phase I Deliverables

• Final Presentation PPT presentation Designed for Biotech Day I To be submitted on May 27th, 23:55 To be presented on June 3rd

• Final Report Stand-alone document – not dependent on presentation Format of Word, PPP, or “hybrid” – you choose Executive Summary - maximum 2 pages in word Can build on June 3rd Final Presentation To be submitted on June 12th, 13:00

Criteria for Uppsala Biotech MC Phase I Deliverables

1. Key issue analysis Clear purpose of investigation Purpose adequately analyzed and fulfilled Appropriate theory and tools used and explained Well substantiated results

2. Presentation Well structured and clear, logical storyline Concise, convincing key messages supported through data or detail Well designed Clearly visualized and within time constraints (Presentation only)

3. Value delivered to company Recommendations that are feasible and actionable Effective in stimulating action Favorable response from Company Interested Q&A from Company (Presentation only)

It’s for the company and

not for me!

Uppsala Biotech MC Deliverables – Final Presentation

Biotech Day I, June 3rd• Biotech Day 5 Minute Presentation (A)

A 5 minute presentation to be made to the entire group of students and company representatives that gives a brief overview of your project, e.g., key issue, method & analysis (i.e., how you went about addressing the key issue), challenges, and lessons learned. But do NOT include conclusions or recommendations due to confidentiality aspects. The idea is to tell others about the type of project that you did and how you went about it so that the audience can learn from your experience if they are faced with doing such a project one day.

• Final Presentation (B) This is the final presentation you will make to your company, but do not see it as the

final product. (The final product is the Final Report to be submitted on June 12th.) Thus, for the Final Presentation to be submitted on May 27th, push as far as you can for closure on your project. You will then have ~3 hours to make this presentation to your company on Biotech Day on June 3rd (1.5 hours in morning, and 1.5 hours after lunch). Use these three hours to discuss things such as issues that might still need some work, your recommendations and how they might be implemented, etc.

I will give you feedback on your presentations hopefully by Monday, May 30th, so that you will have some time to make changes before the presentation on Friday, June 3rd.

Don’t forget to take a look at the Storyboard Approach document that I handed out recently for some presentation tips. In addition to the content of the presentation, I will be looking for things such as a clear, logical storyline and key messages on each slide. See Criteria for Phase I Deliverables slide in this document for more information.

Uppsala Biotech MC Deliverables – Final Report

Due June 12th, 13:00• Remember who the reader is!

This report is to be written for your company. One idea is to ask your company how they intend to use this report, e.g., developing new internal routines, approaching VCs for financing, etc., and then tailor it appropriately.

Please write the report so that if anyone from your MC company picks it up, he or she can understand what it is about.

Use the SSE MBA template and give a background of SSE MBA, MBA Live, the Master Case, and who you are.

I will give you feedback on this report before we present it to the company. In some cases, some of this feedback may need to be incorporated before we present it.

• Keep the reader’s attention! This report (in Word) may build on your Final Presentation to the company, thus

you may use the powerpoint slides in the body of the document. If you do this, then discuss these slides in the body of your report, label them as figure x, and refer to the figures in the body of the report.

Keep the report eye-catching by using headings, bullet points, and figures. Summarize each section with a key message either in the margin next to the

section or highlighted at the end of the section. These key messages should tell the story throughout the report so that it makes it easy for the reader to follow.

Look at the Connecting Firms Master’s thesis that I handed out in your rooms as an example.

The Uppsala Biotech Master CaseBiotech Day


June 3, 2005

Uppsala Biotech Day I – June 3rd, 2005

At SSE MBA• Morning Coffee Mingle • Overview of Uppsala Biotech Master Case

MBA Teams, Sponsor Organization Reps, and SSE MBA Faculty together MBA Teams present Summaries of their Uppsala Biotech Master Case Project (5

minutes each) (A)

• Presentation of Key Issue Recommendations Break out into group rooms Each MBA Team presents its report and recommendations to its Sponsor Organization

individually (B)

• Lunch at SSE MBA Suite• Presentation of Key Issue Recommendations

MBA Team presentations and discussions continue in group rooms (B Cont’d.) Sponsor Organization Reps prepare their feedback and comments on the Key Issue

Recommendations by the MBA Team

• Feedback by Sponsor Organization Representatives MBA Teams, Sponsor Organization Reps, and SSE MBA Faculty together Sponsor Organization Reps give their feedback on their MBA Team’s work Plenary Q&A session

9:00- 9:309:30-10:30

10:30-12:00

12:00-13:00

13:00-14:30

14:30-15:30

Feedback by Sponsor Organization to MBA Team

Please prepare a brief presentation on the following: Your group’s Key Issue Your group’s presentation Value delivered to you by your group Any other thoughts, feedback, or constructive

criticism?

See hand-out for more information







Biotech Day I


Diego


Biotech Symposium

Dynamics of Regional Innovation Systems II CourseTrip to San Diego, June 18-25, with Prof. M. Walshok

ItineraryCO 69 18 June Arlanda-New York, Newark 0925/1210CO 1426 Newark-San Diego 1735/2023 CO 1827 25 June San Diego-Newark 0800/1628CO 68 25 June Newark-Arlanda 1800/0755 (26/6)

Sun Mon Tue Wed Thu Fri Sat

19 20 21 22 23 24 25

10:00: Orientationto campus and

programOverview of

campus, city, program resources

Walk to beach (optional)

Free evening

Theme: The Research Base8:30-11:45

Lectures12:00 Lunch with

life-sci entrepreneur

1:45-2:45 Orientation to projects

3:00-4:30 Tour One: The Research Mesa

(possibly on foot)

Theme:Knowledge

Transfer Mechanisms

8:30-10:00 Lecture10:15-11:45

CONNECT as a Catalyst for Innovation

12:00 Lunch with CONNECT posterchild

1:45-3:15 (+) Tour Two: Sorrento Valley, North City West, Visit to Qualcomm

Theme:Sources of Capital8:30-10:00

Overview of Funding Sources: VC’s, Angels, Corporate Partners

10:15-11:45 TCA presentation

12:00 Lunch with entrepreneur who has been thro gamut of financing

1:45-3:15 (+) Work on projects

Evening (gametime 7:05): Baseball game SD Padres vs. LA Dodgers

Theme:Globalization; and

Service Sector Infrastructure

8:30-10:00 Globalization of

Innovation10:15-11:45

Lecture on service sector

12:00 Lunch with local entrepreneur or service sector representative

1:45-2:45: Clusters (Mary and Orjan)

Remainder of afternoon: work on projects

PresentationsMorning: completion of

projects 12:00: Lunch1:00-4:30 Student

presentations6:30: Farewell dinner and

Midsummer Celebration (Mary’s house)

Depart San Diego

(8:00am flight)

The Final Stretch Uppsala Biotech MC Phase II

Deliverables


June 24, 2005

The Final Stretch• Friday, June 24th (in San Diego)

Presentation of Symposium Poster Presentation (Draft) 20 minutes total for discussion for each team in afternoon

• Monday, June 27th Class Meeting, 13:15-15:00, practical preparation for Symposium Professor Walshok’s Individual Reflection due 17:00

• Tuesday, June 28th Final Symposium Poster Presentation & Hand-out due, midnight

• Wednesday, June 29th Class Meeting, 9:00-12:00, Presentation of Poster Presentation to class Class Meeting, 13:15-17:00, Preparation for Symposium, booths, etc.

• Thursday, June 30th Symposium, 7:00–14:00 Symposium clean-up, 14:00-17:00

Uppsala Biotech MC Phase II Deliverables

• Symposium Poster PresentationPresentation to fit within one large poster (TBA)Designed for discussion with public at Biotech SymposiumFinal due June 28th, midnight

• Symposium Poster Hand-outStand-alone document – Builds on PresentationFormat of Word, PPT, or “hybrid” – you chooseMinimum 9 pagesTo be handed out to public at Symposium Final due on June 28th, midnight

Poster Presentation

• What is a poster? A visually accessible summary of a project

A means for many people to share a lot of information in a short period of time

• Key Components What are the primary points/findings?

What sources did you use?

How can the reader go forward? E.g., websites, organizations, etc.

Biotech Symposium MBA Student Poster Themes

• MBA Team Uppsala BIO-X How to attract “smart money”? Early commercialization from finance

perspective, VC methods, criteria

• MBA Team QUIAtech How to change the entrepreneurial mindset from molecules to money?

• MBA Team Resistentia How to do research more efficiently? A focus on China

• MBA Team Svanova Contrasting European and US VC funding: What can Sweden/Nordic region

learn and improve?

• MBA Team Pharmacia What are the major challenges of introducing an OTC product in the

Californian/US market?

• MBA Team GE Healthcare How to merge large corporate culture and professionalism into a smaller

biotech company? Both perspectives

Criteria for Uppsala Biotech MC Phase II Deliverables

1.Key theme analysis Clear focus Focus adequately analyzed and fulfilled Appropriate theory and tools used and explained

2.Symposium Poster Presentation & Hand-out Well structured and clear, logical storyline Concise, convincing key messages supported through data or

detail Well designed and clearly visualized

3.Value delivered to general public Effective in stimulating discussion Interested Q&A from Symposium public If appropriate, recommendations that are feasible and actionable

It’s for the public and not for me!

Uppsala Biotech MC Phase II Deliverables

• Remember who the reader is!These deliverables are for the general public. Please write the hand-out so that if anyone picks it

up, he or she can understand what it is about.Use the SSE MBA template and give a background

of SSE MBA, MBA Live, the Master Case, and who you are.

• Keep the reader’s attention!Keep the deliverables eye-catching by using

headings, bullet points, and figures.

Symposium on Issues Shaping Nordic

Competitiveness in Biotechnology

Stockholm School of Economics (SSE)Master of Business Administration Program

(MBA)June 30, 2005

Symposium Practical Activities by Students

• Symposium Set-up (7:30 to 9:00) MBA Team BIO-X

MBA Team GE Healthcare

• Symposium Registration (8:00 – 9:00) MBA Team Pharmacia

• Symposium Clean-up (14:00 – 16:00) MBA Team Resistentia

MBA Team Svanova

MBA Team QUIAtech

SSE MBA Student Participation in Symposium

• Presentation of SSE MBA in Symposium Introduction “Why is Biotech Interesting for Business Schools?” by Emil S.

• Participation in Panel Discussions No presentation, but participate in discussion 1 hr 15 min for each panel One student on each panel

• Company Perspective by Krish S. • Policy Perspective by Barbara K.

• Presentation of MBA Poster Themes Introduction of Poster Session by Tony F.

• Poster Discussion During coffee break and one hour session after panel discussions One presentation per group, all group members participate

Issues Shaping Nordic Competitiveness in BiotechnologyIssues Shaping Nordic Competitiveness in BiotechnologySSE MBA Inaugural Symposium

June 30th, Stockholm School of Economics, Sveavägen 65, Stockholm

Stockholm School of Economics

Dr. Ketels has led competitiveness projects across the globe, including work on the Massachusetts Biotech Cluster, and is currently conducting an analysis of the competitiveness of the greater Stockholm region with the OECD.

Keynote Speaker IMads ØvlisenChairman of the BoardNovo Nordisk A/S

Mads Øvlisen is Chairman of the Board as well as former President and CEO of Novo Nordisk. He is also Chairman of LEGO A/S, the Danish Royal Theatre, and the Wanås Foundation and Adjunct Professor at the Copenhagen Business School.

To register (free), contact Helena Kvist-Åslund,

[email protected], +46 (8) 736-9598

In addition to SSE MBA students, other Session Panelists include:Johan Christenson, Partner, HealthCap Nigel Darby, VP, GE HealthcareLaura Howard, MD, Morgan Stanley, UK Ulf Landegren, Professor, Uppsala Univ. Björn Nilsson, SVP, Biacore Mats Pettersson, CEO, BiovitrumPeter Sellei, VP, Investor AB Ylva Williams, Director, Life Science, ISA

Keynote Speaker II Dr. Christian KetelsHead Prof. Porter’s Research Team Institute of Strategy and CompetitivenessHarvard Business School

SSE MBA Biotech Symposium

Time Event Thursday, June 30, 2005

Registration

Symposium Welcome Robin Teigland, SSE MBA

Session II. The Policy PerspectiveNordic Biotech in 2020 – Copying the US or Finding its Own Model?Speaker: Christian Ketels, Harvard Business SchoolPanel Moderator: Robin Teigland, SSE MBA

Session I. The Company PerspectiveHow Do We Overcome the Challenges Facing Nordic Biotech Firms?Speaker: Mads Øvlisen, Chairman, Novo NordiskPanel Moderator: Hans Nyctelius, President, SwedenBIO

SSE MBA Poster Session and Coffee Break

Symposium Wrap-Up Björn Nilsson, SVP, Biacore; Chairman, SwedenBIO

Light Lunch, Mingle, and SSE MBA Poster Session (cont’d)

9:00 - 9:15

8:30 - 9:00

9:15 - 10:30

10:30 - 11:00

11:00 - 12:15

12:15 - 12:30

12:30 - 14:00

Issues ShapingNordic Competitiveness

in Biotechnology

June 30, 20059:00 to 14:00

Stockholm School of EconomicsSveavägen 65

Session I Panelists•Nigel Darby has 17 years of academic research experience, mainly in molecular biology, after which he worked at Astra Zeneca. Currently, he is VP at GE Healthcare, responsible for R&D & Product Management in the protein separations business.•Laura Howard is Managing Director in Morgan Stanley's European Healthcare Group, responsible for the European Biotech Franchise. Prior to her 10 years at Morgan Stanley, she worked with the MAC Group and Goldman Sachs. •Ulf Landegren is Professor at Uppsala University where he heads the Research Group on Molecular Medicine in the Department of Genetics and Pathology.•Mats Pettersson is CEO of Biovitrum since its founding in 2001. Prior to Biovitrum, Mats was SVP and Member of the Management Committee of Pharmacia Corporation. Mats has a B.Sc. in Economics and Business Administration. •Krish Sailam is an SSE MBA student. He has worked with business strategy for both MNCs and start-ups in Asia Pacific and North America with commercialization of technology from the university level.

Session II Panelists•Johan Christenson has a PhD from Karolinska Institute and has held management positions at Astra and Astra Zeneca. He is currently a Partner at HealthCAP.•Barbara Kraus is an SSE MBA student and has previously worked with Accenture. She holds a law degree from the university of Passau and has studied and worked extensively in the Czech Republic and Russia. •Björn Nilsson has over 20 years experience in the pharmaceutical and biotech industry in both commercial and scientific roles. He chairs the Swedish biotechnology organization (SwedenBIO) and serves as SVP at Biacore International AB. •Peter Sellei is responsible for the Healthcare Sector in the Core Holdings Department at Investor AB. He has considerable experience as an academic researcher at Karolinska and as an analyst at firms such as Carnegie and Orkla.•Ylva Williams is Director of the Bio Science Project at the Invest in Sweden Agency. She has an MSc from the Royal Institute of Technology in molecular biology and has considerable managerial experience at VWR International and Pharmacia Biotech.

Symposium Introduction Speech •Emil Sunvisson is an SSE MBA student, honored with the MBA Leadership Award. He holds am MSc from the Royal Institute of Technology and is founder and chairman of Billskill AB, a company enabling telecom operators.

SSE MBA Poster Session Introduction•Tony Friede is an SSE MBA student, and his previous responsibilities include representing the Nordic region within Cap Gemini's global steering committee for CRM. He holds a BSc in Electrical Engineering from the University of Kansas.

SESSION I. THE COMPANY PERSPECTIVE

Keynote Speaker: Mads ØvlisenChairman of the Board, Novo Nordisk A/SMads Øvlisen is former president and CEO of Novo Nordisk and is chairman of several boards: the Danish Royal Theatre, LEGO A/S, and the Wanås Foundation, Sweden. He is also an adjunct professor at the Copenhagen Business School.

Moderator: Hans NycteliusPresident, SwedenBIOHans Nyctelius has seventeen years of working experience from the Life Science industry with the last six years in management consultancy at Arthur D. Little and the Boston Consulting Group. He also holds an MBA with distinction from the Warwick Business School (UK).

SESSION II. THE POLICY PERSPECTIVE

Keynote Speaker: Dr. Christian KetelsHead of Professor Michael Porter’s Research Team Institute of Strategy and CompetitivenessHarvard Business SchoolDr. Ketels has led competitiveness projects across the globe, including work on the Massachusetts Biotech Cluster, and is a member of numerous economic advisory groups in Europe and the Americas. He holds a PhD (Econ) from the London School of Economics.

Moderator: Robin TeiglandCore Faculty, SSE MBARobin Teigland’s teaching interests parallel her research interests as she teaches “The Uppsala Biotech Cluster”, a live case that SSE MBA offers its students. She holds a BA (Econ) with distinction from Stanford and an MBA from Wharton, and prior to obtaining her PhD at SSE, she worked as a consultant with McKinsey & Co.

For information on the other participants, please see the back.

8:30 – 9:00

9:00 – 9:15

9:15 – 9:30

10:30 – 11:00

11:00 – 12:15

12:15 – 12:30

12:30 – 14:00

Registration

Symposium Welcome Robin Teigland, SSE MBA Emil Sunvisson, SSE MBA

Session I. The Company Perspective:How Do We Overcome the Challenges Facing Nordic Biotech Firms? Speaker: Mads Øvlisen, Novo Nordisk Moderator: Hans Nyctelius, SwedenBIO Panelists: Nigel Darby, GE Healthcare Laura Howard, Morgan Stanley Ulf Landegren, Uppsala University Mats Pettersson, Biovitrum Krish Sailam, SSE MBA

SSE MBA Poster Session & Coffee Break Tony Friede, SSE MBA

Session II. The Policy Perspective: Nordic Biotech in 2020 – Copying the US or Finding its Own Model? Speaker: Christian Ketels, HBS Moderator: Robin Teigland, SSE MBA Panelists: Johan Christenson, HealthCap Barbara Kraus, SSE MBA Björn Nilsson, Biacore International Peter Sellei, Investor AB Ylva Williams, Invest in Sweden Agency

Symposium Wrap-up Björn Nilsson, Biacore International

Light Lunch & SSE MBA Poster Session (cont.)

Today’s Program

SSE MBA Poster ThemesImproving Commercialization of Research

How to Choose VC Funding

Interested in China for Biotech R&D?

M&A Management: A Must for Biotech

California 101 – Working within a Californian Biotech Culture

Stockholm/Uppsala - A Unified Bio ZoneCollaboration for Regional and Global Competitiveness

Symposium Write-up in Sweden’s Largest

Newspaper

More Symposium Information

• For more information on the symposium, please visit SwedenBio’s homepage at www.swedenbio.com http://www.swedenbio.com/templates/Page.aspx?id=1367

The posters and speaker presentations can also be found here

Uppsala Biotech MC Contact Information

Robin TeiglandUppsala Biotech MC CoachStockholm School of

Economics08-736 [email protected]/MBAwww.knowledgenetworking.or

g

Martin VidaeusUppsala Biotech MC Advisor070-232 [email protected]

Madeleine Neil Uppsala BIO Communications018-57 23 53 0768-29 77 [email protected]

Feel free to contact Robin at any time!